Stephen Holgate is MRC Clinical Professor of Immunopharmacology at the Faculty of Medicine, Southampton. He has utilised many approaches to study the pathophysiology and treatment of asthma. This research has informed guidelines on asthma management and has identified and validated novel therapeutic targets. He has published >1000 peer review outputs achieving a citation h index of 185. He is cofounder of Synairgen to develop inhaled interferon-b for viral respiratory diseases, including COVID-19. He chaired two Academy of Medical Sciences Reports (2020 and 2021) for the Government Chief Scientist on preparedness for COVID-19 and a more recent discussion on lessons learnt during the pandemic. He is a past president of the British Society for Allergy, Clinical Immunology and British Thoracic Society and the Collegium International Allergologicum(CIA). He has been Chair of MRC Population and Systems Medicine Board, the MRC Translational Research Group and Member of MRC and NERC Strategy Boards. He is a member of the Natural Environment Research Council, Special Advisor to the Royal College Physicians on Air Quality and UK Research and Innovation Clean Air Champion. He was appointed CBE in 2011 for Clinical Science and Knighted in 2020 for Medical Research.
Prof Sir Stephen Holgate CBE FMedSci
MRC Clinical Professor of Immunopharmacology at the Faculty of Medicine, Southampton